CLAIMS

1. AZD9833 for use in the treatment of cancer, wherein the AZD9833 is administered orally once daily at a dose between 25 mg and 450 mg.

2. AZD9833 for use according to claim 1, wherein the dose of AZD9833 is selected from 25 mg, 75 mg, 150 mg, 300 mg and 450 mg.

3. AZD9833 for use according to any of the preceding claims, wherein the AZD9833 is administered as a single dose unit or as multiple dose units.

4. AZD9833 for use according to claim 3, wherein the AZD9833 is administered as a single tablet.

5. AZD9833 for use according to any of the preceding claims, wherein the AZD9833 is administered in combination with a further anti-cancer therapy.

6. AZD9833 for use according to any of the preceding claims, wherein the AZD9833 is administered in combination with a CDK inhibitor.

7. AZD9833 for use according to claim 6, wherein the AZD9833 is administered in combination with palbociclib, ribociclib, abemaciclib, lerociclib or trilaciclib.

8. AZD9833 for use according to any of the preceding claims, wherein the AZD9833 is administered in combination with palbociclib.

9. AZD9833 for use according to any of claims 1 to 5, wherein the AZD9833 is administered in combination with an mTOR inhibitor.

10. AZD9833 for use according to claim 9, wherein the AZD9833 is administered in combination with everolimus.

11. AZD9833 for use according to any of the preceding claims, wherein the cancer is selected from breast cancer and gynaecological cancer.

12. AZD9833 for use according to claim 11, wherein the cancer is ER-positive HER2-negative advanced breast cancer.

13. AZD9833 for use according to any of the preceding claims, wherein the AZD9833 is administered to a pre- or post-menopausal woman.

14. AZD9833 for use according to any of the preceding claims, wherein the cancer has previously been treated with ≥1 endocrine therapy and ≤2 prior chemotherapies for ER-positive HER2-negative advanced breast cancer.

15. AZD9833 for use according to any of the preceding claims, wherein the AZD9833 is administered to a patient whose cancer is resistant to non-steroidal aromatase inhibitors.

16. AZD9833 for use according to any of the preceding claims, wherein the dose of AZD9833 achieves a mean peak blood plasma concentration in a cancer patient of between 10 and 1000 ng/mL.

17. AZD9833 for use according to any of the preceding claims, wherein the dose of AZD9833 achieves a median terminal half-life between 8h and 14h in a cancer patient.

18. AZD9833 for use according to any of the preceding claims, wherein the dose of AZD9833 achieves a median terminal half-life of 12h in a cancer patient.

19. AZD9833 for use according to any of the preceding claims, wherein the dose of AZD9833 achieves an objective response rate between 10% and 20%.

20. AZD9833 for use according to any of the preceding claims, wherein the dose of AZD9833 does not cause any serious side-effects in a cancer patient.

21. A method of treating cancer in a human or animal patient in need of such treatment, comprising administering to the patient AZD9833 orally once daily at a dose between 25 mg and 450 mg.

22. The use of AZD9833 in the manufacture of a medicament for the treatment of cancer, wherein the AZD9833 is administered orally once daily at a dose between 25 mg and 450 mg.

23. A pharmaceutical composition for once daily oral administration comprising between 25 mg and 450 mg of AZD9833 and a pharmaceutically acceptable excipient.

24. A pharmaceutical composition according to claim 23, wherein the amount of AZD9833 is selected from 25 mg, 75 mg, 150 mg, 300 mg and 450 mg.

25. A pharmaceutical composition according to claim 23 or claim 24 in the form of a single tablet.

26. A pharmaceutical composition according to any of claims 23 to 25 for use in the treatment of cancer.

27. A kit comprising a pharmaceutical composition comprising AZD9833 and at least one pharmaceutically acceptable excipient and instructions for the use of the pharmaceutical composition in the treatment of cancer, wherein the AZD9833 is for once daily administration at a dose between 25 mg and 450 mg.

28. A kit according to claim 27, further comprising an additional anti-cancer agent for administration in combination with AZD9833.